

## **Annex I**

**Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)**

### **Scientific conclusions**

Taking into account the PRAC Assessment Report on the PSUR(s) for BCG vaccine (freeze-dried), the scientific conclusions are as follows:

Immune reconstitution inflammatory syndrome (IRIS) was reported in relation with BCG vaccination in the literature and in the post-marketing setting in immunocompromised children. Although it is a known phenomenon during immune system recovery therapy that immune reactions to previous BCG vaccination may appear, PRAC recommended the inclusion of a warning for healthcare professionals in the product information. No update to the package leaflet (PL) is necessary, as the warning is already well reflected there.

The CMDh agrees with the scientific conclusions made by the PRAC.

### **Grounds for the variation to the terms of the Marketing Authorisation(s)**

On the basis of the scientific conclusions for the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing BCG vaccine (freeze-dried) is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing BCG vaccine (freeze-dried) are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

## **Annex II**

**Amendments to the product information of the nationally authorised medicinal product(s)**

**Amendments to be included in the relevant sections of the Product Information** (new text **underlined and in bold**, deleted text ~~strike through~~)

#### Summary of Product Characteristics

- Section 4.4

A warning should be added as follows:

**Cases of Immune reconstitution inflammatory syndrome (IRIS) have been reported after the onset of antiretroviral therapy in HIV-infected children or after initiating treatment for other severe immune deficiencies in children who had prior BCG vaccination. Adenitis, suppurative adenitis, purulent discharge, skin ulceration, skin abscesses, fever, have been reported in association with IRIS, appearing within weeks to months after initiation of immune therapy. Clinicians should be aware of this syndrome when treating patients with primary or secondary immunodeficiency who had prior BCG vaccination.**

### **Annex III**

#### **Timetable for the implementation of this position**

## Timetable for the implementation of this position

Adoption of CMDh position:	November 2018 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	29 December 2018
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	27 February 2019